SEOM clinical guideline of venous thromboembolism (VTE) and cancer (2019)

• A. J. Muñoz Martín ^[1] ; E. Gallardo Díaz ^[7] ; I. García Escobar ^[2] ; R. Macías Montero ^[8] ; V. Martínez-Marín ^[3] ; V. Pachón Olmos ^[4] ; P. Pérez Segura ^[5] ; T. Quintanar Verdúguez ^[6] ; M. Salgado Fernández ^[9]
  1. [1] Instituto de Investigación Sanitaria Gregorio Marañón

     Instituto de Investigación Sanitaria Gregorio Marañón

     Madrid, España

     
  2. [2] Hospital General de Ciudad Real

     Hospital General de Ciudad Real

     Ciudad Real, España

     
  3. [3] Hospital Universitario La Paz

     Hospital Universitario La Paz

     Madrid, España

     
  4. [4] Hospital Ramón y Cajal

     Hospital Ramón y Cajal

     Madrid, España

     
  5. [5] Hospital Clínico San Carlos de Madrid

     Hospital Clínico San Carlos de Madrid

     Madrid, España

     
  6. [6] Hospital General Universitario de Elche

     Hospital General Universitario de Elche

     Elche, España

     
  7. [7] Parc Taulí Hospital Universitari
  8. [8] Complejo Hospitalario Universitario Badajoz
  9. [9] Complexo Hospitalario Universitario de Ourense

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 22, Nº. 2 (February), 2020 (Ejemplar dedicado a: Clinical Guides in Oncology), págs. 171-186
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • In 2011, the Spanish Society of Medical Oncology (SEOM) first published a clinical guideline of venous thromboembolism (VTE) and cancer. This guideline was updated in 2014, and since then, multiple studies and clinical trials have changed the landscape of the treatment and prophylaxis of VTE in cancer patients. To incorporate the most recent evidence, including data from direct oral anticoagulants (DOACs) randomized clinical trials, SEOM presents a new update of the guideline.